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Autoimmune pancreatitis (AIP) has been recognized as a distinct type of pancreatitis that is possibly caused by
autoimmune mechanisms. AIP is characterized by high serum IgG4 and IgG4-positive plasma cell infiltration in affected
pancreatic tissue. Acute phase AIP responds favorably to corticosteroid therapy and results in the amelioration of
clinical findings. However, the long-term prognosis and outcome of AIP remain unclear. We have proposed a working
hypothesis that AIP can develop into ordinary chronic pancreatitis resembling alcoholic pancreatitis over a long-term
course based on several clinical findings, most notably frequent pancreatic stone formation. In this review article, we
describe a series of study results to confirm our hypothesis and clarify that: 1) pancreatic calcification in AIP is closely
associated with disease recurrence; 2) advanced stage AIP might have earlier been included in ordinary chronic
pancreatitis; 3) approximately 40% of AIP patients experience pancreatic stone formation over a long-term course,
for which a primary risk factor is narrowing of both Wirsung’s and Santorini’s ducts; and 4) nearly 20% of AIP patients
progress to confirmed chronic pancreatitis according to the revised Japanese Clinical Diagnostic Criteria, with
independent risk factors being pancreatic head swelling and non-narrowing of the pancreatic body duct.
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Autoimmune pancreatitis (AIP) has been recognized as
a distinct type of pancreatitis that is possibly caused by
autoimmune mechanisms [1-3]. AIP is characterized by
pancreatic enlargement and irregular narrowing of the
main pancreatic duct (MPD), both of which resemble
the imaging features of pancreatic cancer [4-8]. Other
prominent features in AIP include high serum IgG4 and
IgG4-positive plasma cell infiltration in affected pancre-
atic tissue, which are used in the serological and patho-
logical diagnosis of AIP, respectively [9-11]. Patients with
AIP respond favorably to prednisolone (PSL) therapy
from clinical, serological, imaging, and pathological per-
spectives [12-16]. In 2011, the International Consensus
Diagnostic Criteria (ICDC) for AIP enabled diagnosis
based on an international standard, and defined type 1
and type 2 AIP according to pathological and clinical* Correspondence: skawapc@shinshu-u.ac.jp
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article, unless otherwise stated.findings [17]. Several institutions in Japan and abroad
have since confirmed the utility of the ICDC [18-21].
Type 1 AIP corresponds to lymphoplasmacytic scleros-
ing pancreatitis (LPSP), and type 2 AIP relates to idio-
pathic duct centric chronic pancreatitis (IDCP) or AIP
with granulocytic epithelial lesion (GEL) [11,22-24].
Type 1 AIP is closely associated with increased serum
IgG4 concentration and IgG4-bearing plasma cell infil-
tration in affected tissue [2,9-11]. It is presumed to have
specific immunological derangement associated with
IgG4, and has now been recognized as a pancreatic
manifestation of IgG4-related disease (IgG4-RD). IgG4-
RD is a recently established disease concept and novel
clinical entity of unknown origin that exhibits multi-organ
involvement and abundant infiltration of IgG4-positive
cells [2,25-28]. Although the long-term prognosis and out-
come of AIP remain unclear, the determination of whether
AIP progresses to chronic pancreatitis over time is a sig-
nificant matter that needs addressing.
We have proposed a working hypothesis that AIP can
develop into ordinary chronic pancreatitis resemblingtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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the following published clinical findings: 1) the clinical
features of AIP have mainly been reported for an acute
state of the disease, in which short-term pancreatic
swelling and severe lymphoplasmacytic infiltration were
described. These symptoms are unlikely to persist over
an extended period of time and are now believed to
manifest as different clinical features in a chronic disease
state; 2) we have described several patients with AIP
who formed pancreatic stones during the course of their
disease [29,30], which is a well-known phenomenon
confirmed by many other studies [14,29-38]. Since pan-
creatic stones are a primary characteristic of ordinary
chronic pancreatitis, it appears that chronic stage AIP
may exhibit symptoms mimicking those of ordinary
chronic pancreatitis; 3) approximately 30-40% of ordin-
ary chronic pancreatitis cases are classified as unidenti-
fied or idiopathic [39,40], wherein some cases of chronic
stage AIP may have been be included; and 4) we mea-
sured serum levels of IgG4 in 175 patients with chronic
pancreatitis who had been diagnosed before 1995, when
the concept of AIP was first proposed, and found high
serum IgG4 concentrations in 7.4% of individuals [30].
This indicated that chronic stage AIP may have resulted
in the development of ordinary chronic pancreatitis.
In order to investigate and clarify the above points, we
evaluated the association between AIP and pancreatic
calcification and arrived at the conclusion that AIP could
indeed progress to confirmed chronic pancreatitis. In
this review article, we describe a series of studies to con-
firm our working hypothesis.
Autoimmune pancreatitis and pancreatic
calcification
We evaluated the long-term outcomes of patients with
AIP and observed that some individuals experienced
pancreatic calcification.
Development of pancreatic calcification
In 1995, Yoshida et al. first proposed a concept of AIP
that was considered to be free from calcification [4]. As
patients with AIP responded favorably to corticosteroid
therapy, the disease was believed to be a non-progressive
condition that did not lead to pancreatic stone formation
and did not progress to an advanced stage of chronic
pancreatitis. Later, it was brought to light that some pa-
tients with AIP experienced pancreatic stone formation,
pancreatic atrophy, and/or irregular dilatation of the
MPD over a long-term course [14,29-38]. Such imaging
findings mimicked those of chronic pancreatitis, suggest-
ing that patients with AIP could progress to this state.
We subsequently examined 42 AIP patients who had
been followed for at least 12 months (median follow-up
period: 54.5 months, range: 13–111 months). Eight patients(19%) developed pancreatic calcification. Because 6 of 11
patients (54.5%) who relapsed had detectable calcification,
pancreatic calcification in AIP became significantly associ-
ated with relapse patients in comparison with non-relapse
patients (p = 0.0019) [29]. Later, we investigated 51 AIP pa-
tients who had been followed for a minimum of 2 years
(median follow-up period: 72 months, range: 24–178
months), among whom 9 (18%) exhibited pancreatic calci-
fication during the disease course. Pancreatic stone disease
was again significantly more frequent in the recurrence
group (7/21, 33%) than in the non-recurrence group (2/30,
7%) (p = 0.014) [30]. These studies suggested that pancre-
atic calcification was closely associated with relapse and
that AIP could transform into ordinary chronic pancreatitis
after multiple recurrences. The main reason for a pre-
sumed association between calcification and relapse may
be attributed to recurrent periductal lymphoplasmacytic
inflammation, which is a characteristic pathological feature
of type 1 AIP [17], that leads to remnant pancreatic duct
stricture resulting in pancreatic juice stasis and intraductal
calcification. Indeed, our later studies disclosed that pan-
creatic calcification was significantly associated with pan-
creatic head swelling and narrowing of both Wirsung’s and
Santorini’s ducts in the pancreatic head region [41]. Recur-
rent parenchymal inflammation with ensuing calcification
may also be a contributive factor in AIP relapse.
Epidemiology of pancreatic calcification
The frequency of pancreatic calcification in AIP ranges
from 4% to 40% [14,29,30,32,34-36,38,41,42]. Hart et al.
conducted an international investigation on AIP and re-
ported that 46 of 659 patients (7%) demonstrated this
condition. Moreover, pancreatic stone formation was sig-
nificantly more frequent in relapse than in non-relapse
subjects (14.4% vs. 4.0%, p < 0.001) [14]. Meanwhile,
Nakazawa et al. reported that 3 of 37 patients (8%) expe-
rienced pancreatic calcification [32], Suzuki et al. wit-
nessed this in 7 of 50 patients (14%) [34], Takuma et al.
observed this in 2 of 50 patients (4%) [36], and Xingang
et al. reported stone formation in 7 of 27 patients (26%)
[38]. Maire et al. examined 28 patients with type 1 AIP
and 16 patients with type 2 AIP, and disclosed that more
than one-third of AIP patients developed pancreatic im-
aging abnormalities of calcification, atrophy, and/or duct
irregularities within 3 years of diagnosis [37]. Further-
more, Takada et al. reported that the incidences of osteo-
pontin expression in centroacinar cells as well as chronic
pancreatitis with calcification in AIP were significantly
greater than those in the normal pancreas (p < 0.05),
which implied that AIP had the potential for pancreatic
calcification over a long-term clinical course [33]. Al-
though it appears evident that some patients with AIP
experience pancreatic stone formation over time, none
of the previous studies have addressed the underlying
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this complication. Discrepancies in the reported frequen-
cies of pancreatic calcification may be explained by differ-
ences in disease activity, observation period, therapeutic
method, and especially maintenance therapy.
Predictors of relapse
Since pancreatic stone formation in AIP was considered
to be closely associated with relapse, we turned to means
of predicting relapse and treating the disease in its early
stage. We investigated the clinical course of a particular
female patient with AIP who had experienced several re-
currences. Serum levels of IgG4 and immune complexes,
as determined by the monoclonal rheumatoid factor
method (IC-mRF), tended to rise several months before
each recurrence had became clinically apparent [8]. For
prediction of further relapses in this patient, it was helpful
to periodically check serum values of IgG4 and IC-mRF.
IC-mRF performed well in predicting relapse at a cutoff
value of 10 μg/dL, with good sensitivity (61.9%), specificity
(70.0%), and efficacy (66.7%). The probability of relapse
was 60% when IC-mRF was >10 mg/dL and 30% when
IC-mRF was <10 mg/dL [30]. Complement factors C3 and
C4 have also been reported as useful markers for monitor-
ing disease activity and tissue damage [43].
The relapse rate of AIP has been estimated at 30% to
50% [12,14,29,30,36,44-50]. Relapse patients generally
experience 1 or 2 recurrences, although this figure is
higher for some. As corticosteroid therapy has been re-
ported to significantly increase the remission rate and
decrease the relapse rate of AIP [12,48], it is considered
to be the standard treatment for inducing remission
[46]. Previous studies have indicated that various factors
at diagnosis, including diffuse pancreatic swelling, jaun-
dice, and elevated values for IgG4, soluble IL2 receptor,
complement, and immune complexes, are significant
predictive factors of relapse [30,36,45,47,48]. Taken to-
gether, careful observation of prodromal symptoms,
serial measurement of activity markers during the follow-
up period, and early intervention and appropriate disease
management with corticosteroids are needed to reduce
the rate of relapse in AIP.
Risk factors for pancreatic stone formation
We have postulated two mechanisms for pancreatic
stone formation in AIP: 1) severe tissue injury attributed
to the specific inflammatory disease processes; and
2) pancreatic juice stasis due to pancreatic duct narrow-
ing. To examine the risk factors underlying pancreatic
stone formation in AIP, we enrolled 69 AIP patients who
had been followed for at least 3 years (median follow-up
period: 91 months, range: 36–230 months) [41]. During
the study period, increased or de novo stone formation
was seen in 28 patients (28/69, 40.6%), who were definedas the stone-forming group. No stones were observed in
32 patients (32/69, 46.4%), who were considered as the
non-stone-forming group. Nine patients who had stones
at diagnosis but showed no change during the course of
the study were excluded. As a result, approximately 40%
of patients with AIP experienced pancreatic stone for-
mation over a long-term course. We compared the two
groups with regard to clinical and laboratory findings,
as well as to computed tomography (CT) and endo-
scopic retrograde pancreatography (ERP) results. Univar-
iate analysis revealed no significant differences in clinical
or laboratory factors associated with AIP-specific inflam-
mation between the two groups. Relapse was more
frequently seen in the stone-forming group, but not
significantly. Interestingly, pancreatic head swelling
(p = 0.006) (Figure 1A) and narrowing of both Wirsung’s
and Santorini’s ducts in the pancreatic head region
(p = 0.010) (Figure 2A) at the time of diagnosis were sig-
nificantly more frequent in the stone-forming group
(Table 1). Representative CT findings are shown in
Figures 1 and 2 of a 67-year-old woman with pancreatic
head swelling due to AIP who experienced pancreatic
stone formation and pancreatic atrophy 27 months later
(Figure 1B, 1C) and of a 69-year-old male AIP patient
with narrowing of both Wirsung’s and Santorini’s ducts
who presented 105 months later with pancreatic stones
(Figure 2B, 2C). Multivariate analysis identified narrow-
ing of both Wirsung’s and Santorini’s ducts as a signifi-
cant independent risk factor for pancreatic stone
formation (OR 4.4, p = 0.019). Even after corticosteroid
therapy, residual pancreatic head swelling and/or nar-
rowing of Wirsung’s and Santorini’s ducts were more
frequently found in stone-forming patients in our cohort
[41]. These results supported the notion that narrowing
of Wirsung’s and Santorini’s ducts in the pancreatic head
region led to pancreatic juice stasis and eventual stone
formation. On the other hand, there were no significant
linkages between stone formation and published well-
known activity markers of AIP and no patients devel-
oped severe pancreatitis, which suggested that the other
hypothesized mechanism, severe tissue injury attributed
to the specific inflammatory process of AIP, was poorly
associated with pancreatic stone formation. Concerning
the distribution of pancreatic stone formation, we noted
multiple calcifications in the pancreatic head region in
addition to stones in the pancreatic body and tail. Of the
4 patients in the stone-forming group exhibiting duct
narrowing in the body and tail of the pancreas, 2 of
them had parenchymal pancreatic stones in downstream
pancreatic regions [41]. Therefore, some cases of stone
formation may be due to factors other than pancreatic
juice stasis by stenosis of Wirsung’s and Santorini’s ducts
that might be associated with tissue damage attributed
to parenchymal inflammation. This study found that
Figure 1 CT findings in a 67-year-old woman with pancreatic head swelling. (A) CT at diagnosis in May 2005 showing pancreatic head
swelling (arrows). (B), (C) CT 27 months later in August 2007 showing pancreatic stone formation and pancreatic atrophy (arrows). Data are
reprinted from Ref. [41] with permission from the Journal of Gastroenterology.
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pancreatic stone formation, although Hirano et al. re-
ported that high ethanol consumption of >50 g/day in-
creased the risk of stone development and pancreatic
atrophy [42]. Further study is needed on the contribu-
tion of alcohol consumption to disease pathogenesis.
Patients with AIP generally respond favorably to PSL ther-
apy [12-16]. However, the efficacy of PSL treatment may
vary depending on the stage and activity of AIP [51,52]. We
consider that patients with AIP who have residual pancreatic
head swelling and/or narrowing of Wirsung’s and Santorini’s
ducts after PSL therapy might be at a more advanced stage
or active state of AIP. In such cases, treatment with PSL
to prevent pancreatic stone formation and progression toFigure 2 ERCP and CT findings in a 69-year-old man with narrowing o
April 2001 showing Wirsung and Santorini duct narrowing (arrowheads). (B
stone formation and pancreatic atrophy (arrow). Data are reprinted from Rechronic pancreatitis may be of limited use, even if the dose
is increased. Furthermore, we found no significant linkages
between pancreatic stone formation and PSL therapy [41],
which suggested that PSL could not halt pancreatic stones
from forming. We nonetheless maintain that in early stage
AIP, intensive PSL therapy has the potential to prevent pan-
creatic stone formation as well as the progression to chronic
pancreatitis. More detailed analyses of maintenance therapy
and follow-up regimens are needed.
Pancreatic stone formation and pancreatic function:
long-term outcomes
With the confirmation of pancreatic stone formation in
AIP, it has become essential to investigate whether thisf both Wirsung’s and Santorini’s ducts. (A) ERCP at diagnosis in
), (C) CT 105 months later in December 2009 showing pancreatic
f. [41] with permission from the Journal of Gastroenterology.
Table 1 Clinical features, laboratory tests, and pancreatic morphology at diagnosis (From Ref. [41])
Stone-forming Non-stone-forming P value
group (n = 28) group (n = 32)
Clinical features Median (range)
Observation period§ 100 (36–165) 90 (36–230) 0.524
Age 67 (47–84) 64.5 (38–81) 0.543
Sex (M/F) 24/4 22/10 0.140
Alcohol (+/−) 20/8 19/12 0.582
Prednisolone (+/−) 25/3 28/4 1.000
Relapse (+/−) 11/17 6/26 0.093
Laboratory tests
Amylase 94 (17–431) 86 (22–478) 0.678
IgG 2187 (892–7236) 2183 (1194–5545) 0.686
IgG4 640 (154–2855) 424 (4–2970) 0.916
C3 91 (33–157) 87 (29–199) 0.538
C4 20.1 (7.7–39.7) 21.3 (1.1–38.7) 0.627
sIL2-R 738 (132–2260) 940 (257–4695) 0.130
CIC 5.1 (1.9–40) 5.5 (1.9–27.5) 0.392
Pancreatic morphology at diagnosis
Pancreatic swelling (by CT)
Head (+/−) 26/2 20/12 0.006*
Body (+/−) 20/8 19/13 0.419
Tail (+/−) 17/11 19/13 1.000
Focal/Segmental-Diffuse 7/21 12/20 0.406
Ductal narrowing in MPD (by ERP)
Head (+/−) 24/4 22/10 0.140
Wirsung + Santorini (+/−) 21/7 13/19 0.010*
Body (+/−) 15/13 19/13 0.795
Tail (+/−) 22/6 24/8 0.770
Focal/Segmental-Diffuse 6/22 11/21 0.390
§Period from AIP diagnosis to the most recent observation (months).
*P < 0.05.
sIL2-R: soluble interleukin 2 receptor, CIC: circulating immune complex,.
MPD: main pancreatic duct.
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crine or endocrine dysfunction, as seen in ordinary chronic
pancreatitis. We compared serum values of amylase and
HbA1c at diagnosis of AIP and at 5 and 8 years later in
non-stone-forming patients, stone-forming patients, and
intraductal stone-forming patients, the latter of which ap-
peared to be at a more advanced stage of stone formation.
Although we found no significant differences among the
groups, serum amylase and HbA1c levels tended to be ab-
normally varied in intraductal stone-forming patients as
compared with non-stone-forming patients [41]. These re-
sults suggest a possible deterioration in pancreatic exocrine
or endocrine function in stone-forming patients with AIP
over a long-term course, albeit with a different pathophysi-
ology from that of ordinary chronic pancreatitis.Maire et al. reported that more than one-third of AIP
patients experienced pancreatic exocrine or endocrine
deficiency in addition to pancreatic calcification, atro-
phy, and/or duct irregularities, within a 3-year period
following diagnosis [37]. Uchida et al. reported in a
long-term follow up series (mean follow-up period:
40.8 months, range: 18–130 months) that pancreatic
exocrine and endocrine function was not necessarily
improved by PSL therapy, which suggested that the effi-
cacy of steroid treatment may be heterogeneous. They
speculated that responsiveness to corticosteroids was
dependent on the stage and activity of AIP and was
probably more effective in the early active phase [51].
Similarly, Hirano et al. uncovered that over a long
course of AIP (mean follow-up period: 60 months,
Table 2 Breakdown of diagnostic imaging findings for
chronic pancreatitis as determined by the revised
Japanese Clinical Diagnostic Criteria for chronic
pancreatitis (From Ref. [54])
Findings of definite chronic pancreatitis (n = 15) Number
a. Stones in pancreatic ducts 9
b. Multiple or numerous calcifications distributed
in the entire pancreas
13
c. Irregular dilatation of the MPD and irregular dilatation of
pancreatic duct branches of variable intensity with scattered
distribution throughout the entire pancreas on ERCP
2
d. Irregular dilatation of the MPD and branches proximal
to complete or incomplete obstruction of the MPD
(with pancreatic stones or protein plugs) on ERCP
2
Findings of probable chronic pancreatitis (n = 1)
b. Irregular dilatation of pancreatic duct branches of variable
intensity with scattered distribution throughout the entire
pancreas, irregular dilatation of the MPD alone, or protein
plugs on ERCP
1
c. Irregular dilatation of the MPD throughout the
entire pancreas plus pancreatic deformity with
irregular contour on CT
0
This study did not evaluate MRCP or US (EUS) findings, so the probable
chronic pancreatitis findings of (a) and (d), which are judged by these
modalities, were excluded.
Figure 3 Images of AIP exhibiting definite chronic pancreatitis, and fi
progression to chronic pancreatitis. (A) CT image of stones in pancreati
distributed throughout the entire pancreas (arrows). CT and ERCP findings
confirmed chronic pancreatitis at diagnosis. (C) CT finding of pancreatic he
non-narrowing in the pancreatic body at AIP diagnosis (arrowheads). (From
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severely compromised did not fully recover, even after
PSL therapy. They recommended PSL therapy at an
early stage of AIP to preserve insulin secretion [52].
The long-term outcome of pancreatic function in AIP
remains unclear, especially with respect to pancreatic
stone formation. It is also difficult to assess the natural
course of pancreatic exocrine and endocrine function be-
cause many patients with AIP are promptly treated with
PSL. Further study is needed to address these matters.
Autoimmune pancreatitis can progress to chronic
pancreatitis
Some patients with AIP exhibit severe pancreatic calcifi-
cation over a long-term course. Pancreatic stones are a
primary characteristic of ordinary chronic pancreatitis,
which suggests that AIP can progress to a form of
chronic pancreatitis that meets the diagnostic criteria for
ordinary chronic pancreatitis.
Serum levels of IgG4 in patients with confirmed chronic
pancreatitis
It has been an interesting matter how many patients
with advanced stage AIP who demonstrated definite
chronic pancreatitis symptoms may have been included
with patients having ordinary chronic pancreatitis be-
fore the proposal of AIP. We previously reported thatndings of AIP demonstrating independent risk factors for
c ducts (arrow). (B) CT image of multiple or numerous calcifications
of AIP demonstrating independent risk factors for progression to
ad swelling at AIP diagnosis (arrows). (D) ERP finding of MPD
Ref. [54]).
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http://www.ojrd.com/content/9/1/77more than 60% of AIP patients maintained high serum
IgG4 concentrations even after clinical symptoms were
resolved [53]. Thus, if advanced stage AIP was previ-
ously included in confirmed ordinary chronic pan-
creatitis, such cases presumably maintained serum
IgG4 elevation. We measured the serum values of
IgG4 in 175 patients with confirmed chronic pancrea-
titis who had been diagnosed before 1995, which was
the year when the concept of AIP was first proposed,
and uncovered raised serum IgG4 in 13 patients


















Pancreatic morphology at diagnosis




Level 1/Level 2Φ 8/8
Ductal narrowing in MPD (by ERP)
Head (+/−) 13/3
Wirsung & Santorini (+/−) 11/5
Body (+/−) 3/13
Tail (+/−) 12/4
Level 1/Level 2Ψ 6/10
Ductal dilatation in MPD (+/−) 9/7
§Period from AIP diagnosis to the most recent observation (months).
ΦSwelling was classified as level 1 (diffuse swelling) or level 2 (focal/segmental swe
Autoimmune Pancreatitis.
ΨPancreatic duct narrowing was classified as level 1 (long [segmental/diffuse] or mu
Consensus Diagnostic Criteria for Autoimmune Pancreatitis.
*P < 0.05.
CP: chronic pancreatitis, PSL: prednisolone, sIL2-R: soluble interleukin 2 receptor,
CIC: circulating immune complex, MPD: main pancreatic duct.alcoholic and 4 idiopathic patients). Among them, 3
had initially been diagnosed as having pancreatic
cancer, and 1 had just previously been given a diag-
nosis of AIP after long-term clinical follow-up. The
remaining 9 patients showed the typical imaging find-
ings of ordinary chronic pancreatitis, including pan-
creatic stones and irregular dilation of the MPD [30].
This indicated that advanced stage AIP might have
formerly been included in the diagnostic criteria for
ordinary chronic pancreatitis, and especially alcoholic
pancreatitis.rphology at diagnosis (From Ref. [54])
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pancreatitis that meets the revised japanese clinical
diagnostic criteria for ordinary chronic pancreatitis
After confirming that chronic AIP may have been included
in ordinary chronic pancreatitis, we next investigated
whether AIP could transform into chronic pancreatitis that
specifically met the revised Japanese Clinical Diagnostic
Criteria (JCDC) and aimed to clarify the susceptibility fac-
tors and underlying mechanisms of AIP progressing to this
state [54]. We enrolled 73 patients with AIP who had been
followed for at least 3 years (median follow-up period:
88 months, range: 36–230 months). Among them, 16 pa-
tients (22%) were confirmed to have chronic pancreatitis
according to the revised JCDC for chronic pancreatitis
[55], which included 15 patients with definite chronic
pancreatitis and 1 patient with probable chronic pancrea-
titis (Table 2). The major imaging findings in definite
cases were stones in pancreatic ducts in 9 patients
(Figure 3A) and multiple or numerous calcifications dis-
tributed throughout the entire pancreas in 13 patients
(Figure 3B). As this study mainly utilized CT and ERP
findings, the probable chronic pancreatitis criteria that
required MRCP or US (EUS) were excluded [54].
Clinical features of autoimmune pancreatitis that meet
the revised japanese clinical diagnostic criteria for
ordinary chronic pancreatitis: risk factors for progression
to chronic pancreatitis
During the course of the above study of 73 patients with
AIP, progression to chronic pancreatitis in terms of the
revised JCDC was seen in 16 patients (22%), who were
defined as the progression group, as compared with the
remaining 57 non-progression group patients who did
not develop chronic pancreatitis. We compared the twoFigure 4 Progression rate for AIP to chronic pancreatitis. (A) Kaplan-M
in 73 patients with AIP. (B) Kaplan-Meier analysis of the progression rate to
pancreatic head swelling and MPD non-narrowing in the pancreatic body.
factor (n = 21) groups. (From Ref. [54]). **P < 0.001 (log-rank test). CP: chronigroups with respect to clinical and laboratory factors, as
well as to CT and ERP findings. Univariate analysis of
clinical features revealed that relapse was significantly
more frequent (p = 0.030) in the progression group. We
found no significant differences in AIP activity markers
between the two groups. In pancreatic imaging findings,
pancreatic head swelling was more frequently seen in
the progression group, albeit not significantly. Interest-
ingly, MPD narrowing in the pancreatic body was sig-
nificantly less frequent (p = 0.001) and MPD dilatation at
one pancreatic area or more was significantly more fre-
quent (p = 0.001) in the progression group (Table 3).
Thirteen patients with AIP having MPD non-narrowing
in the pancreatic body contained 8 individuals with di-
lated duct diameter, all of whom showing simultaneous
pancreatic head swelling. Furthermore, multivariate ana-
lysis indicated that pancreatic head swelling (OR 12.7,
p = 0.023) and MPD non-narrowing in the pancreatic
body (OR 12.6, p = 0.001) were significant independent
risk factors for the progression to chronic pancreatitis
[54]. There were 15 patients with pancreatic head swell-
ing in the progression group, 7 of whom with localized
swelling mainly in the pancreatic head (so-called focal
type) and 8 of whom with diffuse swelling of the pan-
creas parenchyma (so-called diffuse type). Similarly,
there were 13 patients with MPD non-narrowing in the
pancreatic body, 12 of whom with simultaneous pancre-
atic head swelling. Of these, 4 patients had localized
swelling mainly in the pancreatic head (so-called focal
type) and 8 patients had diffuse swelling of the pancreas
parenchyma (so-called diffuse type). This study uncov-
ered differences between risk factors for pancreatic stone
formation and progression to chronic pancreatitis. The
reason for this discrepancy might be that the formereier analysis of the progression rate to confirmed chronic pancreatitis
confirmed chronic pancreatitis in AIP based on the risk factors of
Comparison of zero risk factor (n = 6), 1 risk factor (n = 45), and 2 risk
c pancreatitis.
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meet the diagnostic criteria of chronic pancreatitis.
Period and ratio of progression to chronic pancreatitis
We witnessed the median time from AIP diagnosis to
chronic pancreatitis to be 33 months (range: 16–124
months) in the above study. Kaplan-Meier testing revealedFigure 5 Sequential progression mechanism of AIP to confirmed chro
ducts (arrows) by pancreatic head swelling causes pancreatic juice stasis in
increased intra-pancreatic duct pressure that is resistant to typical AIP-spec
non-narrowing in this region (arrowheads). (C) In concert with relapse, thethat the progression rate to chronic pancreatitis was 10%
at 36 months, 20% at 100 months, and 30% at 124 months
(Figure 4A). Advancement to chronic pancreatitis was not
observed after 124 months, suggesting that the window
for disease development was within 10 years of follow-up.
Next, we performed stratification analysis for AIP progres-
sion to chronic pancreatitis using the two risk factorsnic pancreatitis. (A) Narrowing of both Wirsung’s and Santorini’s
the upstream pancreatic duct. (B) Pancreatic juice stasis results in
ific MPD narrowing in the pancreatic body region, leading to MPD
se events finally result in severe calcification. (From Ref. [54]).
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ing and MPD non-narrowing in the pancreatic body.
Kaplan-Meier testing was performed on 3 groups: the zero
risk factor group (6 patients), the 1 risk factor group
(45 patients), and the two risk factor group (21 patients).
No AIP patients progressed to chronic pancreatitis in the
zero risk factor group. The 2 risk factor group showed a
significantly higher progression rate (30% at 3 years
and 60% at 10 years) than did the 1 risk factor group
(p < 0.001, log-rank test) (Figure 4B) [54]. We could there-
fore recommend careful follow-up of patients with AIP
having these 2 risk factors to prevent progression to
chronic pancreatitis.
Mechanism of autoimmune pancreatitis
progressing to chronic pancreatitis
Based on our cumulative study outcomes, we have
proposed the hypothesis of a sequential progression
mechanism of AIP to chronic pancreatitis: many cases
of AIP include pancreatic head swelling during the
acute stage, some of which lead to long-standing nar-
rowing of both Wirsung’s and Santorini’s ducts in this
region, which may then cause pancreatic juice stasis
in the upstream pancreatic duct (Figure 5A). This
might later induce increased intra-pancreatic duct
pressure that is resistant to typical AIP-specific MPD
narrowing in the pancreatic body, causing MPD non-
narrowing in this region (Figure 5B). In concert with
relapse, these events may ultimately result in severe
calcification of the entire pancreas and pancreatic at-
rophy (Figure 5C) [54].
Limitations and future perspectives
There are several limitations to this review. Specifically,
our earlier study designs included a limited number of pa-
tients and were mainly retrospective in nature. They also
applied the revised JCDC for chronic pancreatitis with a
strong emphasis on imaging findings, and the subjects en-
rolled were primarily patients with type 1 AIP. Due to our
reliance on imaging findings, more detailed analysis of
physical findings, exocrine and endocrine dysfunction, and
pathological findings in advanced stage AIP showing se-
vere pancreatic calcification is needed.
Conclusions
Over the last decade, it has been become apparent that
some patients with AIP can experience pancreatic stone
formation, pancreatic atrophy, and/or irregular dilatation
of the MPD over a long-term course, which may shed
light on the matter of whether or not AIP can progress
to confirmed chronic pancreatitis. This cumulative study
has clarified the following points: 1) pancreatic calcifica-
tion in AIP is closely associated with disease recurrence;
2) advanced stage AIP might have earlier been includedin ordinary chronic pancreatitis; 3) approximately 40%
of patients with AIP experience pancreatic stone forma-
tion over a long-term course, for which a primary risk
factor is narrowing of both Wirsung’s and Santorini’s
ducts; and 4) nearly 20% of AIP patients progress to
confirmed chronic pancreatitis according to the revised
JCDC, with independent risk factors of pancreatic head
swelling and MPD non-narrowing in the pancreatic
body. Finally, AIP can lead to severe pancreatic stone
formation and progress to confirmed chronic pancrea-
titis over a long-term period, which may be most pre-
sumably caused by disease recurrence and pancreatic
juice stasis. From these observations, we believe that it is
necessary for patients with AIP to maintain a carefully
devised follow-up regimen to prevent possible progres-
sion to chronic pancreatitis.
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